venBio Partners LLC Long-Term Concentrated

CIK: 0001776382 · Show all filings

Period: Q4 2022 (← Previous) (Next →)

Filing Date: Feb 14, 2023

Total Value ($000): $322,544 (100.0% shares, 0.0% debt)

Holdings (7)

VTYX VENTYX BIOSCIENCES INC 35.2%

Value ($000) $113,504 Shares 3,461,536 Est. Cost $18.95 Unrealized +56.3%

ALXO ALX ONCOLOGY HLDGS INC 33.9%

Value ($000) $109,318 Shares 9,699,925 Est. Cost $39.31 Unrealized -71.4%

HRMY HARMONY BIOSCIENCES HLDGS IN 17.7%

Value ($000) $57,050 Shares 1,035,396 Est. Cost $36.46 Unrealized +50.8%

PHVS PHARVARIS N V 8.0%

Value ($000) $25,838 Shares 2,296,710 Est. Cost $31.46 Unrealized -83.3%

— IMPEL PHARMACEUTICALS INC 3.2%

Value ($000) $10,349 Shares 2,759,791 Est. Cost $8.85 Unrealized —

— CINCOR PHARMA INC 1.5%

Value ($000) $4,712 Shares 383,390 Est. Cost $17.64 Unrealized —

— ELEVATION ONCOLOGY INC 0.5%

Value ($000) $1,773 Shares 1,866,339 Est. Cost $13.57 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
VTYX	VENTYX BIOSCIENCES INC	3,461,536	$113,504	35.2%	$18.95	+56.3%	COM	92332V107
ALXO	ALX ONCOLOGY HLDGS INC	9,699,925	$109,318	33.9%	$39.31	-71.4%	COM	00166B105
HRMY	HARMONY BIOSCIENCES HLDGS IN	1,035,396	$57,050	17.7%	$36.46	+50.8%	COM	413197104
PHVS	PHARVARIS N V	2,296,710	$25,838	8.0%	$31.46	-83.3%	COM	N69605108
—	IMPEL PHARMACEUTICALS INC	2,759,791	$10,349	3.2%	$8.85	—	COM	45258K109
—	CINCOR PHARMA INC	383,390	$4,712	1.5%	$17.64	—	COM	17240Y109
—	ELEVATION ONCOLOGY INC	1,866,339	$1,773	0.5%	$13.57	—	COM	28623U101